Skip to main content

Following negotiations with manufacturer Roche, Health Secretary Vaughan Gething has announced that breast cancer drug Kadcyla®, will be routinely available on the Welsh NHS.

First published:
20 June 2017
Last updated:

This was published under the 2016 to 2021 administration of the Welsh Government

Roche has now agreed with NHS Wales the same commercial access agreement as NHS England. This means that Welsh patients with certain types of advanced breast cancer will be able to benefit from the treatment.

The Welsh Government’s £80 million New Treatment Fund has been designed to ensure new medicines such as Kadcyla® can be made available as soon as possible, and certainly within two months of the recommendation from NICE.

Health Secretary, Vaughan Gething, said:

“I am very pleased to be able to announce that Kadcyla® has been approved for use in Wales following negotiations with the manufacturer.  

“We are committed to improving the introduction of innovative, evidence-based, treatments, which is why we’ve introduced an £80 million treatment fund in Wales. The fund will be used to ensure patients get fast-access to this innovative, life-prolonging drug.”